Danting Zhang

No. 2000 Jiangyue Road
Shanghai, 201112, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Distinct anti-MDA5 antibody trajectories associated with long-term outcomes in 6-month survivors of anti-MDA5 dermatomyositis with interstitial lung disease.

Distinct anti-MDA5 antibody trajectories associated with long-term outcomes in 6-month survivors of anti-MDA5 dermatomyositis with interstitial lung disease.

Journal: Respiratory research
Published: September 23, 2025

Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial.

Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial.

Journal: Annals of the rheumatic diseases
Published: August 07, 2025

A prospective multicenter randomized controlled trial pre-emptive increase in immunosuppression for asymptomatic serological reactivation in patients with lupus nephritis in clinical remission.

A prospective multicenter randomized controlled trial pre-emptive increase in immunosuppression for asymptomatic serological reactivation in patients with lupus nephritis in clinical remission.

Journal: Kidney international
Published: May 24, 2025

Cluster of differentiation-44 as a novel biomarker of lupus nephritis and its role in kidney inflammation and fibrosis.

Cluster of differentiation-44 as a novel biomarker of lupus nephritis and its role in kidney inflammation and fibrosis.

Journal: Frontiers in immunology
Published: June 03, 2024

Effectiveness and Safety of Belimumab in Chinese Lupus Patients: A Multicenter, Real-World Observational Study.

Effectiveness and Safety of Belimumab in Chinese Lupus Patients: A Multicenter, Real-World Observational Study.

Journal: Biomedicines
Published: January 29, 2023

Four trajectories of 24-hour urine protein levels in real-world lupus nephritis cohorts.

Four trajectories of 24-hour urine protein levels in real-world lupus nephritis cohorts.

Journal: RMD open
Published: December 12, 2022

WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease.

WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease.

Journal: Rheumatology (Oxford, England)
Published: October 12, 2022

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial.

Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial.

Journal: RMD open
Published: August 22, 2022

Two clusters of systemic lupus erythematosus patients with muscle involvement in a Chinese cohort.

Two clusters of systemic lupus erythematosus patients with muscle involvement in a Chinese cohort.

Journal: International journal of rheumatic diseases
Published: May 30, 2022

Analysis of microRNA-199a-3p expression in CD4+ T cells of systemic lupus erythematosus.

Analysis of microRNA-199a-3p expression in CD4+ T cells of systemic lupus erythematosus.

Journal: Clinical rheumatology
Published: May 09, 2022

Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity.

Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity.

Journal: Lupus science & medicine
Published: January 05, 2022

Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial.

Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial.

Journal: Lupus science & medicine
Published: December 11, 2021
Showing 1-12 of 21

Last Updated: 09/26/2026